Why the study?
Despite an increased CAD prevalence in COPD patients, dedicated diagnostic recommendations are lacking, and whether COPD patients receive adequate primary CAD evaluation despite overlapping symptoms is unclear.
Does the presence of COPD affect the delay of invasive coronary angiography referral and the applicability of symptom-based CAD risk scores compared to matched controls?
Does the presence of COPD affect the delay of invasive coronary angiography referral and the applicability of symptom-based CAD risk scores compared to matched controls?
Current symptom-based risk scores for stable coronary artery disease are inappropriate for patients with COPD, leading to significant delays in referral for invasive coronary angiography.
Answers are grounded in this paper and cite their sources.
Should not yet change CAD evaluation; leaves open whether the association generalizes beyond this cohort.
BACKGROUND: Cardiovascular diseases are arguably the most important comorbidity in patients with COPD. Despite an increased prevalence of coronary artery disease (CAD) in COPD patients, there are no dedicated diagnostic recommendations. OBJECTIVES: We investigated whether COPD patients receive adequate primary evaluation of CAD despite overlapping symptoms. METHODS: In total, 302 patients with COPD who underwent invasive coronary angiography (ICA) were retrospectively matched (for age, body mass index and cardiovascular risk factors) with 302 patients without functional lung diseases. Quality and onset of symptoms prior to ICA were documented, and individual patients' pretest probabilities according to European Society of Cardiology (ESC) guidelines were calculated. Endpoints were delay of ICA referral after symptom onset and clinical outcome, defined as subsequent revascularisation. RESULTS: 26.8%, p=0.015). Sub-analysis of Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades revealed an incremental delay with increasing COPD severity: GOLD 1: 16.1±17.3 months; GOLD 2: 17.6±22.1 months; GOLD 3: 20.1±21.3 months; and GOLD 4: 24.2±23.4 months. Overall significant CAD prevalence (>70% stenosis) was 35.3%; the revascularisation rate increased with higher pretest probability for the control group but decreased for patients with COPD GOLD 1-4. CONCLUSION: Patients with COPD are insufficiently evaluated for CAD due to overlapping symptoms. Current CAD risk scores for stable chest pain appear inappropriate for patients with COPD.
No takes yet. Share an insight, caveat, or question.
Beyer et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: